T

    TransMedics Group Inc (TMDX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $84.87
    -3.56 (-4.03%)

    Market Cap: $3.07B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(18/30)
    Avg Surprise
    +136.47%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.30
    Range$0.15 - $0.40
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    6
    30d
    EPS Estimate Drift
    90d ago$0.45+49.1%
    60d ago$0.45+51.7%
    30d ago$0.39+30.7%
    7d ago$0.30+0.0%
    Current$0.30
    Revenue Consensus
    $177M
    Range$170M - $188M
    11 analysts
    Dec 31, 2026
    EPS Consensus$0.17
    Range$-0.22 - $0.33
    9 analysts
    Revenue Consensus
    $207M
    Range$192M - $218M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.17---
    Sep 26EST
    		-$0.30---
    Jun 26
    		$0.44$0.50-12.00%Miss-52.2%
    Mar 26
    		$0.30N/A-50.82%Miss-57.1%
    Dec 25
    		$0.05N/A-86.94%Miss-73.2%
    Sep 25
    		$0.66$0.36+83.33%Beat+450.0%
    Jun 25
    		$0.92$0.43+113.95%Beat+162.9%
    Mar 25
    		$0.70$0.24+191.67%Beat+100.0%
    Dec 24
    		$0.19$0.22-13.64%Miss+58.3%
    Sep 24
    		$0.12N/A-62.50%Miss+71.4%
    Jun 24
    		$0.35$0.20+75.00%Beat+1266.7%
    Mar 24
    		$0.35$0.01+3400.00%Beat+537.5%
    Dec 23
    		$0.12$-0.03+500.00%Beat+157.1%
    Sep 23
    		$0.07$-0.13+153.85%Beat+128.0%
    Jun 23
    		$-0.03N/A+76.92%Beat+92.7%
    Mar 23
    		$-0.08N/A+66.67%Beat+78.9%
    Dec 22
    		$-0.21$-0.30+30.00%Beat+54.3%
    Sep 22
    		$-0.25$-0.41+39.02%Beat+46.8%
    Jun 22
    		$-0.41$-0.34-20.59%Miss-5.1%
    Mar 22
    		$-0.38$-0.39+2.56%Beat-31.0%
    Dec 21
    		$-0.46$-0.42-9.52%Miss-100.0%
    Sep 21
    		$-0.47$-0.37-27.03%Miss-147.4%
    Jun 21
    		$-0.39$-0.29-34.48%Miss-8.3%
    Mar 21
    		$-0.29$-0.30+3.33%Beat+31.0%
    Dec 20
    		$-0.23$-0.25+8.00%Beat+46.5%
    Sep 20
    		$-0.19$-0.33+42.42%Beat+51.3%
    Jun 20
    		$-0.36$-0.45+20.00%Beat+18.2%
    Mar 20
    		$-0.42$-0.40-5.00%Miss+91.4%
    Dec 19
    		$-0.43$-0.40-7.50%Miss+59.0%
    Sep 19
    		$-0.39$-0.45+13.33%Beat-56.0%
    Jun 19
    		$-0.44$-0.44+0.00%Beat-
    Mar 19
    		$-4.86$-0.98-395.92%Miss-
    Dec 18
    		$-1.05$0.00N/AMiss-
    Sep 18
    		$-0.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio58.49EV/EBITDA27.47x
    Price/FCF37.13xFCF Yield2.69%
    Profitability
    Profit Margin22.70%Operating Margin12.50%
    ROE36.30%ROIC9.09%
    Financial Health
    Debt/Equity0.99xInterest Coverage4.42x
    Current Ratio6.62xQuick Ratio6.07x
    Trading Statistics
    Beta1.88Avg Volume910.69K
    52-Week High$156.0052-Week Low$60.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$91.47
    SMA 20$88.37
    SMA 50$79.36
    SMA 200$105.36
    EMA 10$89.67
    EMA 20$87.68
    EMA 50$83.50
    EMA 200$95.45

    MACD

    Line: 3.15Signal: 4.01Hist: -0.86

    ADX

    ADX: 25.9+DI: 23.3-DI: 25.9

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down28.0
    PSAR$95.04

    Bollinger Bands

    Upper Band$98.29
    Lower Band$78.45
    %B Position2245%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    47.8

    Momentum Oscillators

    Stoch %K40.2
    Stoch %D61.3
    Williams %R-81.6
    ROC (10d)-3.9%
    Momentum-3.48
    CCI (20d)-44.5
    MFI (14d)36.9

    Volatility Measures

    ATR (14d)$4.11(4.8%)
    StdDev (20d)4.96
    Hist Vol51.9%(High)

    Volume Flow

    VWAP$85.14
    OBV-2.2M
    AD Line-5.6M
    CMF (20d)0.394

    Volume Metrics

    Avg Vol (20d)880.3K
    Vol Ratio1.3x
    VWMA (20d)$85.95

    Pivot Points

    R3$96.88
    R2$95.16
    R1$91.80
    Pivot Point$90.08
    S1$86.72
    S2$85.00
    S3$81.64

    Advanced Oscillators

    TSI21.72
    Ultimate Osc50.1
    KST209.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$189.95M$173.93M$160.76M$143.82M$157.37M$143.54M$121.62M$108.76M$114.31M$96.85M$81.17M$66.43M
    Cost of Revenue$76.75M$72.77M$67.35M$59.25M$60.78M$55.31M$49.61M$47.92M$45.04M$36.89M$33.25M$25.77M
    Gross Profit$113.20M$101.16M$93.41M$84.58M$96.59M$88.23M$72.01M$60.84M$69.26M$59.96M$47.92M$40.66M
    Operating Expenses$89.46M$87.86M$72.14M$61.27M$60.02M$60.78M$63.37M$56.92M$56.75M$47.54M$45.32M$69.00M
    R&D$31.63M$24.88M$20.70M$15.26M$15.93M$17.16M$16.46M$14.27M$13.86M$11.38M$10.76M$38.34M
    SG&A$57.83M$62.98M$51.44M$46.02M$44.09M$43.63M$46.91M$42.66M$42.90M$36.16M$34.56M$30.65M
    Operating Income$23.74M$13.30M$21.27M$23.30M$36.57M$27.44M$8.64M$3.92M$12.51M$12.42M$2.60M$-28,335,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$7.22M$7.17M$3.35M$3.49M$3.48M$3.46M$3.57M$3.62M$3.62M$3.60M$3.60M$3.59M
    Income Before Tax$19.41M$8.48M$21.63M$23.03M$36.18M$26.68M$6.99M$4.25M$12.15M$12.39M$3.86M$-26,929,000
    Income Tax Expense$4.72M$1.17M$-83,750,000$-1,288,000$1.27M$994,000$132,000$29,000$-41,000$196,000$-168,000$-1,507,000
    Net Income$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M$4.22M$12.19M$12.20M$4.03M$-25,422,000
    EBITDA$36.87M$27.52M$32.45M$33.37M$46.39M$36.27M$16.24M$13.04M$20.38M$20.29M$11.07M$-21,446,000
    EBIT$26.63M$15.65M$24.99M$26.52M$39.66M$30.14M$10.56M$7.86M$15.78M$15.99M$7.47M$-23,339,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789, REGN is ~1% above Vulcan's $778 BFV. Not cheap. Not expensive. The market has priced in the base case, leaving alpha entirely in when you buy not if. Dupixent is a compounding machine: Seven US indications and growing, co-commercialized with Sanofi. This isn't just an eczema drug, it's a type-2 inflammation platform that funds REGN's entire R&D pipeline. Fortress balance sheet, real tail risk: D/E of 0.1, 120x interest coverage, Altman Z of 7.8. Yet the 5-year max drawdown is -59.7%. Quality doesn't prevent drawdowns. The alpha zone: Buy zone $715–$730 (~9% pullback). Strong buy $625. Current price above both. Set alerts. No chasing. The patient investor wins here.

    Unknown Author
    •
    2/27/26
    •
    155
    Biotech
    BioPharma
    Also mentions:
    SNY
    AMGN
    TMDX
    GILD

    Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

    Tonight's earnings confirmed the thesis: Q4 revenue $160.8M (+32%), FY $605.5M (+37%), 5,139 OCS cases (+38%), 2026 guidance $727M–$757M. TMDX has graduated from speculative disruptor to verified logistics monopoly. The 22-aircraft fleet is the moat: NOP bundled revenue converts device sales into recurring per-case logistics contracts at 60% gross margins. Building this fleet is what the market punished in 2023 and what it's reprici ROIC 12.1% now exceeds WACC 10.2% (+190 bps spread). This was negative during fleet buildout. Value creation is now confirmed, not projected. Healthcare Barbell context: (GILD) Part 1 is the income anchor, low beta, undervalued, 4%+ yield. (TMDX is the growth compounder. (REGN) Part 3 is the pipeline optionality. Three positions, three roles, one coherent thes

    Unknown Author
    •
    2/25/26
    •
    127
    healthcare-innovation
    Healthcare Stocks
    Also mentions:
    GILD
    REGN

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined lenacapavir guide for 2026. Arcellx acquisition ($7.8B) adds anito-cel CAR-T for multiple myeloma. FDA decision Dec 23, 2026. Logical Kite extension, but differentiation burden is real. At ~17x forward EPS ($8.45-$8.85 guided), you pay fair value for the base and get oncology pipeline optionality essentially free. 2.1% yield while you wait. Vulcan scores: 93 Overall, 93 Value, 88 Quality, 95 Sentiment. Altman Z 4.6, Piotroski F 7, ROIC 19.6%, 78.7% gross margins. Fortress fundamentals. Part 1 of the Healthcare Barbell series: GILD anchors with defensive cash flows (0.37 beta). Part 2 (TMDX) and Part 3 (REGN) incoming. Invalidation: Biktarvy YoY declines in two consecutive quarters or EPS guides lower.

    Unknown Author
    •
    2/24/26
    •
    119
    Healthcare Stocks
    healthcare-innovation
    Also mentions:
    TMDX
    REGN
    JNJ

    Why TransMedics Stock is a Buy for Long-Term Investors

    TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash: $250K consoles + $80–100K per-procedure recurring revenue + the scaling National OCS Program (NOP) aircraft fleet. Margins expanding, FCF inflection is real. Financials are inflecting sharply: EPS beat (+83%), strong operating leverage, rising gross margins, and guidance moving higher even with temporary revenue noise. Short-term volatility ≠ broken thesis: Stock recently sold off on a slight revenue miss and high short interest, but fundamental adoption trends remain strong across transplant centers. Long-term runway is substantial: Multi-organ expansion, NOP scaling, higher utilization rates, and future indications (including kidney) create years of growth. GNG Research Rating — BUY on weakness: Best accumulation zone is sub-$110, with long-term fair value well above current levels based on sustained growth, rising margins, and expanding TAM.

    Unknown Author
    •
    11/14/25
    •
    266
    medical-technology
    healthcare-innovation
    organ-transplant
    growth-stocks
    Also mentions:
    ISRG
    SYK
    MDT
    ABT
    EW

    News

    TransMedics Group, Inc. (TMDX) Stock Analysis: Exploring Growth Potential with a Robust 36.29% ROE

    TransMedics Group, Inc. (TMDX) is a medical technology company specializing in organ transplant therapy, demonstrating strong financial performance with a 36.29% return on equity and 20.70% revenue growth. The stock trades near its average target price, with analysts largely issuing buy recommendations, indicating confidence in its growth potential despite market volatility. The company's focus on reinvestment rather than dividends positions it as an appealing option for growth-oriented investors.

    DirectorsTalk Interviews•8/24/26•
    Bullish

    EP Wealth Advisors LLC Purchases Shares of 15,401 TransMedics Group, Inc. $TMDX

    EP Wealth Advisors LLC recently acquired a new stake of 15,401 shares in TransMedics Group, Inc., valued at approximately $1.02 million, bringing institutional ownership of the company's stock to 99.67%. Despite mixed analyst ratings and a consensus "Hold" rating, TransMedics reported strong quarterly revenue growth of 20.7%, though earnings per share missed consensus estimates. The stock currently trades significantly below its 12-month high, reflecting a volatile market performance.

    MarketBeat•8/24/26•
    Neutral

    Biondo Investment Advisors LLC Purchases New Position in TransMedics Group, Inc. $TMDX

    Biondo Investment Advisors LLC has acquired a new stake of 44,155 shares, valued at approximately $2,933,000, in TransMedics Group, Inc. during the second quarter. Other institutional investors also bought new stakes in the company, bringing the total institutional ownership to 99.67%. The article also discusses recent analyst ratings, the company's financial performance, and a recent insider stock sale.

    MarketBeat•8/24/26•
    Neutral

    30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC

    Emerald Investment Advisers LLC recently acquired 30,456 shares of TransMedics Group, Inc. (NASDAQ:TMDX) valued at approximately $2.02 million, contributing to institutional investors owning 99.67% of the company. Despite reporting strong revenue growth, TransMedics missed earnings per share estimates, and analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $124.18.

    MarketBeat•8/23/26•
    Neutral

    Deutsche Bank AG Makes New Investment in TransMedics Group, Inc. $TMDX

    Deutsche Bank AG has acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 217,031 shares valued at approximately $14.415 million, representing about 0.63% of the company. Other institutional investors have also adjusted their positions in TMDX, with 99.67% of the stock owned by hedge funds and institutions. The article also notes recent stock performance, earnings results where the company missed EPS estimates but beat revenue expectations, and a recent insider stock sale.

    MarketBeat•8/23/26•
    Somewhat-Bullish

    Frequently Asked Questions About TMDX

    Does TMDX pay dividends?
    TransMedics Group Inc (TMDX) does not currently pay a regular dividend.
    What is TMDX's P/E ratio?
    TransMedics Group Inc has a price-to-earnings (P/E) ratio of 58.49.
    What is TMDX's market cap?
    TransMedics Group Inc (TMDX) has a market capitalization of $3.07B with a current stock price of $84.87.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In